UBS Group
TCRT icon

UBS Group’s Alaunos Therapeutics TCRT Stock Holding History

UBS Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-667
Closed -$634K – 7974
2017
Q1 		$634K Buy
+667
New +$621K ﹤0.01% 3876
2015
Q1 		– Sell
-33
Closed -$25K – 9357
2014
Q4 		$25K Buy
+33
New +$17.5K ﹤0.01% 7327

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

UBS Group's TCRT Position: Q2 2026 in Review

UBS Group reduced its Alaunos Therapeutics (TCRT) stake by 56% in Q2 2026, selling an estimated $3.27K and leaving 992 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #9378.

UBS Group first reported a position in TCRT in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.52M in Q4 2015. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • UBS Group held 992 shares of Alaunos Therapeutics worth $2.24K as of Q2 2026.
  • UBS Group sold 1,282 Alaunos Therapeutics shares in Q2 2026, an estimated $3.27K.
  • Alaunos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9378 holding.
  • UBS Group first reported a position in Alaunos Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Alaunos Therapeutics position peaked at $7.52M in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.